Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iolab

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson subsidiary receives a patent covering laser technology for fragmentation of cataracts prior to replacement with intraocular lenses. The probe incorporating the technology, which "is designed to be less invasive" than ultrasonic phacoemulsification, pulses laser energy onto a target in the device that converts the laser energy to soundwave energy. Iolab says the device can fit through 2.4 mm incisions as opposed to the 3 mm or greater required for phacoemulsification. In addition, "no heat is generated at the incision site," the firm says. Iolab has exclusive, world-wide development and marketing rights to the product, which was developed by patent recipient Jack Dodick, MD, Manhattan Eye, Ear and Throat Hospital. Six procedures were performed with the laser in 1991 under an investigational device exemption. More trials are slated for 1995
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002583

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel